SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 20 |
| Revenue | 4M USD (2021) |
Ayala is a clinical-stage oncology company formed after acquiring an exclusive, worldwide license to its product candidates AL101 and AL102 from Bristol-Myers Squibb (BMS). It is focused on developing and commercializing small molecule therapeutics for patients living with rare and aggressive cancers, especially in genetically defined patient populations. Ayala is based in Wilmington, Delaware.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-02-06 |
Ayala Pharmaceuticals - AL102
Rehovot, Pennsylvania, United States Ayala Pharmaceuticals' AL102 is an investigational small molecule gamma-secretase inhibitor currently being evaluated in the randomized Phase 3 RINGSIDE international trial for the treatment of desmoid tumors – a debilitating soft tissue malignancy. Ayala Pharmaceuticals' AL102 is based in Rehovot, Pennsylvania. |
Sell | - |
